01-25-2012: Spinnovation announces that it further anchors its presence in the US market through the collaboration with Quantum Tessera in Collegeville, Pennsylvania. This exciting extension to the business came after the Company trebled the number of clients in the biotech and pharma markets last year. Dr Edward Zartler from Quantum Tessera, will be working with Spinnovation to develop biologic and biosimilar characterisation markets in the US.

Dr Frederic Girard, CEO of NMR services specialist Spinnovation said “The new presence in the US has enabled us to take advantage of the expanding interest in bioprocess technologies to support the manufacture of biologics. We are gaining momentum with new companies in new markets, and are very excited to see what the future holds.”

Contact / Request information

Request further information free of charge:

More about Spinnovation Analytical
  • News

    Spinnovation expands into the US

    Spinnovation announces that it further anchors its presence in the US market through the collaboration with Quantum Tessera in Collegeville, Pennsylvania. This exciting extension to the business came after the Company trebled the number of clients in the biotech and pharma markets last year ... more

    Spinnovation launch new biologics division with unique service provision

    Frederic Girard, CEO Spinnovation Analytical BV announced the launch of a new division of the company – Spinnovation Biologics – at the annual meeting of the Flanders Biotech group. Extending the company’s current contract research and contract analysis services, the new division will provi ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE